(Z)-十八碳-9-烯-12-炔酸 | 2277-31-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: (Z)-十八碳-9-烯-12-炔酸
• 英文名称: crepenynic acid
• 英文别名: (Z)-octadec-9-en-12-ynoic acid
• CAS: 2277-31-8
• 化学式: C₁₈H₃₀O₂
• 分子量: 278.435
• InChiKey: SAOSKFBYQJLQOS-KTKRTIGZSA-N

物化性质

• 熔点：
  10.5-11.0 °C
• 沸点：
  370.4±17.0 °C(Predicted)
• 密度：
  0.936±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  20
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916190090

反应信息

• 作为反应物：
  描述：

  (Z)-十八碳-9-烯-12-炔酸 在 草酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-((Z)-Heptadec-8-en-11-ynyl)-4,4-dimethyl-4,5-dihydro-oxazole
  参考文献：
  名称：

  Mass spectrometry of fatty acids with methylene-interrupted ene-yne systems

  摘要：

  When crepenynic acid and octadec-14-yn-17-enoic acid were converted to 4,4-dimethyloxazoline (DMOX) derivatives by the usual procedure. considerable isomerization occurred. The former was converted in part to 7-(5-pentyl-cyclohexadienyl)-heptadecanoate, as was confirmed by mass spectrometry, including preparation of a Diels-Alder adduct with 4-methyl-1,2,4-triazoline-3,5-dione. A mild procedure for preparation of dimethyloxazoline derivatives was therefore developed that did not cause such artefact formation. The mass spectra of the dimethyloxazoline and picolinyl ester derivatives of the two acids are described. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.

  DOI：

  10.1016/s0009-3084(98)00016-4
• 作为产物：
  描述：

  methyl cis-octadec-9-en-12-ynoate 在 氢氧化钾 、 乙醇 作用下， 生成 (Z)-十八碳-9-烯-12-炔酸
  参考文献：
  名称：

  A New Type of Naturally Occurring Polyunsaturated Fatty Acid

  摘要：

  DOI：

  10.1021/jo01025a016

文献信息

• FORMULATIONS FOR THE DELIVERY OF ACTIVE AGENTS TO INSECTS, PLANTS, AND PLANT PATHOGENS
  申请人：Preceres Inc.

  公开号：US20170325457A1

  公开（公告）日：2017-11-16

  The present disclosure is directed to formulations comprising (1) at least one formulation transport agent, (2) at least one complexing agent, and (3) at least one active agent that modulates one or more traits of a target insect, plant, or plant pathogen. The present disclosure is also directed to methods of delivering such formulations to the target organism, as well as to formulation transport agents used to prepare such formulations.

  本公开涉及包含（1）至少一种制剂运输剂、（2）至少一种络合剂和（3）至少一种调节目标昆虫、植物或植物病原体的一个或多个特征的活性剂的配方。本公开还涉及将这种配方传递给目标生物体的方法，以及用于制备这种配方的制剂运输剂。
• MANUFACTURE, METHOD AND USE OF ACTIVE SUBSTANCE-RELEASING MEDICAL PRODUCTS FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN
  申请人：Hoffmann Erika

  公开号：US20100063585A1

  公开（公告）日：2010-03-11

  The invention relates to stents and catheter balloons having optimized coatings for eluting rapamycin as well as methods for manufacturing these coatings.

  本发明涉及具有优化涂层以释放雷帕霉素的支架和导管球囊，以及制造这些涂层的方法。
• MANUFACTURE, METHOD AND USE OF DRUG-ELUTING MEDICAL DEVICES FOR PERMANENTLY KEEPING BLOOD VESSELS OPEN
  申请人：Hoffmann Erika

  公开号：US20130005758A1

  公开（公告）日：2013-01-03

  The invention relates to stents and catheter balloons having optimized coatings for eluting rapamycin as well as methods for manufacturing these coatings.

  本发明涉及具有经过优化的涂层以释放雷帕霉素的支架和导管球囊，以及制造这些涂层的方法。
• DERIVATIVES OF DIHYDROXYPHENYLALANINE
  申请人：Susilo Gisela

  公开号：US20090285888A1

  公开（公告）日：2009-11-19

  The invention relates to derivatives of dihydroxyphenylalanine, to their synthesis and to pharmaceutical compositions containing said derivatives of dihydroxyphenylalanine. Furthermore, the invention relates to the use of said derivatives of dihydroxyphenylalanine and said pharmaceutical compositions for the treatment and prophylaxis of movement disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, hemiparkinson-hemiatrophy, parkinsonian syndrome, Lewy body disease, frontotemporal dementia, Lytico-Bodig disease (parkinsonism/dementia/amyotrophic lateral sclerosis), striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration, progressive atrophy of the globus pallidus, progressive supranuclear palsy, Hallervorden-Spatz disease, Huntington's disease, X-linked dystonia-parkinsonism (Lubag), mitochondrial cytopathy with striatal necrosis, neuroacanthocytosis, restless legs syndrome, Wilson's disease.

  本发明涉及二羟基苯丙氨酸衍生物、其合成方法以及含有该二羟基苯丙氨酸衍生物的制药组合物。此外，本发明还涉及使用该二羟基苯丙氨酸衍生物和该制药组合物治疗和预防运动障碍、神经退行性疾病、阿尔茨海默病、帕金森病、半侧帕金森萎缩症、帕金森综合症、Lewy小体病、颞叶额叶痴呆、Lytico-Bodig病（帕金森症状/痴呆/肌萎缩性侧索硬化症）、纹状体黑质变性、Shy-Drager综合症、散发性橄榄桥小脑变性、球状体进行性萎缩、进行性核上性麻痹、Hallervorden-Spatz病、亨廷顿病、X连锁性肌张力障碍帕金森症（Lubag）、线粒体细胞病伴有纹状体坏死、神经棘细胞病、不宁腿综合症、威尔逊病的用途。
• DEVICE AND METHOD FOR SOLUBILIZING, SEPARATING, REMOVING AND REACTING CARBOXYLIC ACIDS IN OILS, FATS, AQUEOUS OR ORGANIC SOLUTIONS BY MEANS OF MICRO-OR NANOEMULSIFICATION
  申请人：Dietz Ulrich

  公开号：US20130090488A1

  公开（公告）日：2013-04-11

  The present invention is directed to solubilizing compounds, a device and a method for solubilizing and removing carboxylic acids and especially fatty acids from oils, fats, aqueous emulsion, aqueous media and organic solutions. Devices utilizing the inventive method shall be used for separating carboxylic acids from oils, fats, aqueous emulsion, lipophilic media or organic solutions, respectively by preparing an aqueous micro- or nanoemulsion of the carboxylic acids especially the fatty acids and the solubilizing compound which contains at least one amidino and/or gianidino group. Solubilization effects of solubilizing compounds combined with the inventive use of separation methods for carboxylic acids can be used to treat persons in need of removal of fatty acids or analyze carboxylic acids from blood or process other solutions in food, pharmacy, chemistry, bio fuel industry or other industrial processings.

  本发明涉及溶解化合物、用于从油、脂肪、水乳液、水介质和有机溶液中溶解和去除羧酸，特别是脂肪酸的装置和方法。采用本发明方法的装置将用于通过制备羧酸特别是脂肪酸和含有至少一种氨基甲酰基和/或肼基团的溶解化合物的水微观或纳米乳液，分离油、脂肪、水乳液、亲脂性介质或有机溶液中的羧酸。溶解化合物的溶解效果与本发明所述的羧酸分离方法相结合，可用于治疗需要去除脂肪酸或从血液中分析羧酸或处理食品、药品、化学、生物燃料工业或其他工业加工过程中的其他溶液的人员。